Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells

Read full text
Authors: W. Vista, Vaishali Malik, Mary Chase Sheehan, Jaad Ismail, Hocine R. Hocine, Undrakh Ganbaatar, Kyohei Misawa, Jesus Guzman Valle, Srijita Banerjee, Stephen B. Solomon, Prasad S. Adusumilli, Govindarajan Srimathveeravalli
Cited by: 3
References: 52

Abstract

PURPOSE: One recurring challenge in cell therapy for solid tumors is poor tumor infiltration of adoptively transferred T cells. We previously showed that a subablative dose of tumor-targeted radiation generates a chemokine gradient that promotes infiltration, proliferation, and a memory phenotype of chimeric antigen receptor (CAR) T cells in solid tumors. However, radiation is cytotoxic to infiltrating CAR T cells, limiting its repeated use. EXPERIMENTAL DESIGN: We hypothesized that irreversible electroporation could generate a chemokine gradient that promotes CAR T-cell infiltration into solid tumors and that selective irreversible electroporation (sIRE) tuned for selective cancer cell lysis (thus sparing infiltrating CAR T cells) can be used in a repeated fashion. Using experimental screening and simulation models, we optimized sIRE parameters to kill cancer cells while sparing T cells. RESULTS: Using 3D tumor mimics and mouse models of malignant pleural mesothelioma, we confirmed the therapeutic benefit of repeated sIRE. Chemokine secretion by cancer cells injured by sIRE promoted migration and tumor infiltration of systemically administered CAR T cells and facilitated sustained immunity in a tumor-rechallenge model. CONCLUSIONS: By leveraging a dual-purpose translational strategy-through direct cancer cell-targeted cytotoxicity and augmented CAR T-cell infiltration-sIRE can reduce cancer burden while preserving and enhancing CAR T-cell function.

Fields of Study & Subjects

CAR-T cell therapy research Microbial Inactivation Methods Immunotherapy and Immune Responses

Publication details

Journal / source
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Volume
32
Issue
13
Pages
2708–2721
Publication date
1 April 2026
Language
EN